CURZION PHARMACEUTICALS
Curzion Pharmaceuticals is a privately held development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825).
CURZION PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2019-01-01
Address:
San Diego, California, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
0
Similar Organizations
Diartis Pharmaceuticals
Diartis Pharmaceuticals is a privately held biopharmaceutical company.
G3 Pharmaceuticals
G3 pharmaceuticals is a development-stage biopharmaceutical company.
Harkness Pharmaceuticals
Harkness Pharmaceuticals is a privately-held development stage biopharmaceutical company.
Investors List
New Enterprise Associates
New Enterprise Associates investment in Venture Round - Curzion Pharmaceuticals
More informations about "Curzion Pharmaceuticals"
Curzion Pharmaceuticals - PitchBook
Curzion Pharmaceuticals General Information Description. Operator of a biotechnology company based in San Diego, California. The company is engaged in the development of oral selective โฆSee details»
Curzion Pharmaceuticals - Products, Competitors, Financials, โฆ
Curzion Pharmaceuticals, Inc. is a privately held development-stage biopharma company that is creating an oral selective lysophosphatidic acid 1 receptor antagonist (LPAR1), CZN001 โฆSee details»
Curzion Pharmaceuticals - Ownership and Business Overview
Apr 2, 2020 Curzion Pharmaceuticals, Inc. is a development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, โฆSee details»
Curzion Pharmaceuticals - Crunchbase
Organization. Curzion Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. Similar Companies. Edit Similar Companies Section. โฆSee details»
Horizon Therapeutics plc Acquires Curzion โฆ
Apr 2, 2020 This press release contains forward-looking statements, including, but not limited to, statements related to the acquisition of Curzion Pharmaceuticals, Inc. and the benefits thereof, Horizonโs ...See details»
Horizon Pharma acquires Curzion Pharmaceuticals - 2020-04-02 ...
Apr 2, 2020 Curzion Pharmaceuticals Curzion Pharmaceuticals is a privately held development-stage biopharma company. Acquiring Organization: Horizon Pharma Horizon Therapeutics โฆSee details»
Curzion Pharmaceuticals - Pappas Capital
Curzion Pharmaceuticals is a clinical-stage company, co-founded by Pappas Capital, focused on developing treatments for rare fibrotic diseases. The company's lead asset is a potent and โฆSee details»
Curzion Pharmaceuticals, Inc.: Drug pipelines, Patents, Clinical trials ...
Jul 5, 2023 Explore Curzion Pharmaceuticals, Inc. with its drug pipeline, therapeutic area, technology platform, 1 news.See details»
CURZION PHARMACEUTICALS, INC. - Address, Director information
11 rows Curzion Pharmaceuticals, Inc. it has been 6 years 1 months, and 12 days since the company registered today. Companies of the same agent name - CORPORATION SERVICE โฆSee details»
Curzion Pharmaceuticals Acquired by Horizon Therapeutics
DUBLIN -- April 2, 2020 -- Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held development-stage biopharma โฆSee details»
Curzion Pharmaceuticals, Inc. - RiverVest
Curzion Pharmaceuticals is developing a late-stage small molecule to treat fibrotic conditions, where significant unmet needs exist. The safety and efficacy of its in-licensed lead โฆSee details»
Curzion Pharmaceuticals Inc. - BioCentury Company Profiles - BCIQ
Apr 2, 2020 Curzion Pharmaceuticals Inc. - BioCentury Company Profiles for the biopharma industrySee details»
Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc.
Apr 3, 2020 Forward Looking Statements. This press release contains forward-looking statements, including, but not limited to, statements related to the acquisition of Curzion โฆSee details»
Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc
Apr 2, 2020 Horizon Therapeutics plc announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held development-stage biopharma company, and its โฆSee details»
Horizon snaps up Curzion Pharma and its ex-Sanofi rare disease โฆ
Apr 3, 2020 Horizon Therapeutics has added to its growing acquisitive pipeline with the buyout of Curzion Pharmaceuticals for just $45 million.. It gains the privately held biotechโs oral โฆSee details»
Curzion Pharmaceuticals - Funding, Financials, Valuation & Investors
Jan 1, 2019 Curzion Pharmaceuticals has raised 1 round. This was a Venture - Series Unknown round raised on Jan 1, 2019 . Curzion Pharmaceuticals is funded by New Enterprise Associates .See details»
Curzion Pharmaceuticals - The Lundbeck Foundation
Curzion Pharmaceuticals Curzion was developing a compound for Diffuse cutaneous systemic sclerosis (dcSSc), a rare, chronic autoimmune disease marked by fibrosis, or skin thickening, โฆSee details»
Curzion Pharmaceuticals - CB Insights
Curzion Pharmaceuticals has 1 board of directors, including Johan Kördel. Name. Firm. Work History. Other Seats. Johan Kördel. Prior to founding Sound Bioventures, Johan was a Senior โฆSee details»
Horizon Therapeutics plc Acquires Curzion Pharmaceuticals
Apr 2, 2020 DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held โฆSee details»